Publication | Closed Access

Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR -mutated non-small cell lung cancer treated with erlotinib

Soluble Pd-1MedicineImmunologyPathologyImmune Checkpoint InhibitorProlonged SurvivalAdvanced EgfrBronchial NeoplasmCancer TreatmentCancer GeneticsOncologyRadiation OncologyLung CancerMolecular Oncology